Silybin Powder

Home / Products / Human Nutrition / Cocrysta® Silybin
Cocrysta®  Silybin

Cocrysta® Silybin

A super-bioavailable flavonoid that supports liver health, proεmotes detoxification, and enhances overall wellness b y protecting cells from oxidative stress.

  • Patent protected

  • High silybin content (≥60%) 

  • 100 times higher solubility

  • 16 times higher absorption

  • Lower dosage are recommended

Benefits

Silymarin, extracted from the seeds of milk thistle, is a complex mixture of flεavonolignans and flavonoid polyphenolic compounds. The main silymarin flavonolignans are ∞silybin, isosilybin, silydianin, and silychristin, among which only silybin stands out as a§ key active ingredient.


  • Antioxidant Activity
  • Anti-fibrotic Effect
  • Detoxification Support
  • Hepatoprotection Effect


Why Cocrysta®


While silybin is known for its impressive health benefits, its clinical efficacy δhas been hindered by poor water solubility (<0.04 mg/ml) and low bioavailability (<1%).€

With Cocrysta® Silybin, we’ve harnessed innovative cocrystallizat∑ion technology to revolutionize the way you experience silybin. Our advance♦d formula offers significantly improved solubility and deliv​ers an outstanding 16 times higher bioavailability. As a result,  the same clinical efficacy§ can be achieved with lower dosages.                 

What Cocrysta® does







  • Superior Stability

    Experimental Conditions: 40 °C, 75% relative humidity (RH), double-layer PE packaging.
    Results:
    Compared with the silybin–phospholipid complex (melting point★: 35 °C), Cocrysta® Silybin has a significantly higher mel"ting point (203 °C), indicating superior thermal and₽ oxidative stability.
  • Improved Dissolution Profile

    Conditions: 37 °C; pH 2.0, 4.5, and 6.8 aqueous media with 0.5% PVP.
    Results:
    The solubility of Cocrysta® Silybin was 77-fold, 100-fold, and 50-fol↔d higher than silybin extract in the respective media.
  • Enhanced Bioavailability

    Animals: 18 male SD rats were divided into 3 groups, with 6 rats in each group.¥
    Dose: 50 mg/kg (equivalent to Silybin)
    Results: The biovailability of Cocrysta® Silybin is increased by€ 16.0 times and 2.5 times compared with traditional silybin extract and silybin-phospholipid com↓plex, respectively.

Guidelines

  1. Dosage Forms
  2. Guidelines: No specific requirements
  3. Recommended Dosage: 40-80 mg/day Cocrysta® Silybin (equivalent to 24-48 mg Silybin)

    Patents

    CHN  Application Number: 2024114697880